Welch & Forbes’s GSK GSK Stock Holding History

Welch & Forbes’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.2M	Hold	518,597	–	–	0.33%	66
2026 Q1	$28.6M	Hold	518,597	–	–	0.37%	65
2025 Q4	$25.4M	Hold	518,597	–	–	0.31%	70
2025 Q3	$22.4M	Sell	518,597 -768	-0.1%	-$30K	0.27%	76
2025 Q2	$19.9M	Hold	519,365	–	–	0.25%	78
2025 Q1	$20.1M	Sell	519,365 -470	-0.1%	-$17.2K	0.26%	79
2024 Q4	$17.6M	Buy	519,835 +16	+0%	+$576	0.23%	80
2024 Q3	$21.3M	Sell	519,819 -832	-0.2%	-$34K	0.27%	78
2024 Q2	$20.1M	Hold	520,651	–	–	0.27%	79
2024 Q1	$22.3M	Hold	520,651	–	–	0.31%	76
2023 Q4	$19.3M	Sell	520,651 -40	-0%	-$1.44K	0.29%	79
2023 Q3	$18.9M	Sell	520,691 -286	-0.1%	-$10.2K	0.31%	77
2023 Q2	$18.6M	Sell	520,977 -124	-0%	-$4.45K	0.29%	80
2023 Q1	$18.5M	Hold	521,101	–	–	0.31%	79
2022 Q4	$18.3M	Buy	+521,101	New	+$17.4M	0.33%	77
2022 Q3	–	Sell	-521,103	Closed	-$28.4M	–	373
2022 Q2	$28.4M	Hold	521,103	–	–	0.52%	55
2022 Q1	$28.4M	Hold	521,103	–	–	0.45%	63
2021 Q4	$28.7M	Hold	521,103	–	–	0.43%	62
2021 Q3	$24.9M	Hold	521,103	–	–	0.41%	64
2021 Q2	$25.9M	Sell	521,103 -320	-0.1%	-$15.4K	0.44%	59
2021 Q1	$23.3M	Sell	521,423 -242	-0%	-$11K	0.43%	64
2020 Q4	$24M	Hold	521,665	–	–	0.47%	55
2020 Q3	$24.5M	Sell	521,665 -261	-0.1%	-$13.1K	0.53%	51
2020 Q2	$26.6M	Hold	521,926	–	–	0.62%	47
2020 Q1	$24.7M	Hold	521,926	–	–	0.69%	47
2019 Q4	$30.7M	Sell	521,926 -101	-0%	-$5.62K	0.68%	50
2019 Q3	$27.9M	Sell	522,027 -721	-0.1%	-$37.1K	0.66%	49
2019 Q2	$26.2M	Sell	522,748 -1,456	-0.3%	-$73.1K	0.64%	52
2019 Q1	$27.4M	Sell	524,204 -83	-0%	-$4.15K	0.69%	49
2018 Q4	$25M	Sell	524,287 -510	-0.1%	-$25.1K	0.71%	47
2018 Q3	$26.4M	Hold	524,797	–	–	0.63%	53
2018 Q2	$26.4M	Sell	524,797 -713	-0.1%	-$35.9K	0.68%	48
2018 Q1	$25.7M	Sell	525,510 -926	-0.2%	-$43.1K	0.66%	52
2017 Q4	$23.3M	Buy	526,436 +838	+0.2%	+$38.7K	0.62%	54
2017 Q3	$26.7M	Buy	525,598 +62	+0%	+$3.15K	0.7%	52
2017 Q2	$28.3M	Sell	525,536 -439	-0.1%	-$23.4K	0.79%	43
2017 Q1	$27.7M	Buy	525,975 +887	+0.2%	+$45K	0.79%	42
2016 Q4	$25.3M	Sell	525,088 -8,026	-2%	-$396K	0.76%	42
2016 Q3	$28.7M	Hold	533,114	–	–	0.99%	31
2016 Q2	$28.9M	Sell	533,114 -3,372	-0.6%	-$178K	0.88%	36
2016 Q1	$27.2M	Buy	536,486 +138,080	+35%	+$6.88M	0.85%	35
2015 Q4	$20.1M	Sell	398,406 -480	-0.1%	-$24.5K	0.64%	56
2015 Q3	$19.2M	Buy	398,886 +880	+0.2%	+$45.8K	0.64%	56
2015 Q2	$20.7M	Sell	398,006 -800	-0.2%	-$45K	0.64%	54
2015 Q1	$23M	Sell	398,806 -240	-0.1%	-$13.8K	0.69%	49
2014 Q4	$21.3M	Sell	399,046 -600	-0.2%	-$33.6K	0.63%	55
2014 Q3	$23M	Sell	399,646 -423	-0.1%	-$25.9K	0.7%	50
2014 Q2	$26.7M	Hold	400,069	–	–	0.84%	42
2014 Q1	$26.7M	Hold	400,069	–	–	0.85%	41
2013 Q4	$26.7M	Sell	400,069 -588	-0.1%	-$38.1K	0.85%	42
2013 Q3	$25.1M	Sell	400,657 -1,749	-0.4%	-$113K	0.85%	43
2013 Q2	$25.1M	Buy	+402,406	New	+$25.5M	0.9%	41

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Welch & Forbes's GSK Position: Q2 2026 in Review

Welch & Forbes held its GSK (GSK) position steady in Q2 2026 at 518,597 shares worth $27.2M. The position accounts for 0.33% of the portfolio, ranked #66.

Welch & Forbes first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $30.7M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Welch & Forbes held 518,597 shares of GSK worth $27.2M as of Q2 2026.
Welch & Forbes left its GSK share count unchanged in Q2 2026.
GSK made up 0.33% of Welch & Forbes's portfolio in Q2 2026, its #66 holding.
Welch & Forbes first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Welch & Forbes's GSK position peaked at $30.7M in Q4 2019.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.